Embio

What Embio does

Embio Limited is a Mumbai-based, privately held pharmaceutical manufacturer founded in 1993 that specializes in the bio-transformation of Active Pharmaceutical Ingredients (APIs), advanced intermediates, and specialty chemicals using synthetic biology and precision fermentation. Its core technology stack spans bacterial, fungal, and Category 1 GMO whole-cell biotransformation in yeast and bacteria, integrated with downstream chromatography-based purification and semi-synthetic organic chemistry steps; the company's Embio Research Center (DSIR-recognized since 2003) runs the process development pipeline while a 425-kiloliter fermentation footprint across 1x10KL, 1x20KL, and 9x40KL fermenters supports commercial-scale production at its Mahad facility, with a new multipurpose intermediate plant under construction at Dahej, Gujarat.

The company holds a distinctive position in Schedule-1 and Schedule-2 controlled-substance manufacturing (including pseudoephedrine, ephedrine, lisdexamfetamine, selegiline, and levodopa), supplying originator and large multinational pharmaceutical companies in regulated markets under US-FDA, PMDA, KFDA, COFEPRIS, WHO-GMP, EMA, and ANVISA approvals. Beyond proprietary API supply, Embio operates a full-service Contract Development and Manufacturing (CDMO) vertical — process development, scale-up from 10L to 40KL, downstream processing, and analytical method development — and a smaller crop-protection line (bio-fertilizers and Trichoderma-based bio-pesticides, 300KL/annum capacity).

Revenue is generated through B2B enterprise sales with quote-based, multi-year contracts negotiated per molecule, regulatory filing requirement, and volume; products reach customers in more than 70 countries via a direct sales team based at the Mumbai corporate office. In May 2026, True North acquired a 25% minority stake for approximately $50 million (implying a $200M valuation), with proceeds earmarked for R&D, Dahej capacity expansion, and CDMO scaling. The company employs approximately 500 people and has filed 23 process patents, of which 10 are commercialized.

Name

Embio

Legal name

Embio Limited

Website

https://embio.co.in

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

251–500 employees

Short description

Embio Limited is a Mumbai-based pharmaceutical manufacturer (founded 1993) that uses synthetic biology and precision fermentation to produce controlled substances, chiral APIs, and advanced intermediates for regulated-market pharma customers across 70+ countries, supplemented by CDMO services and bio-fertilizers.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

akta.pro secondary industry

Biological Formulation, Fermentation & Scale-Up Manufacturing (AFABAEAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• Controlled substance manufacturing
• Chiral molecule synthesis
• Bio-fertilizers production

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacture and sale of APIs including pseudoephedrine, ephedrine, levodopa, CBD, lisdexamfetamine, selegiline for regulated markets. Products backed by USDMF, KDMF, CEP filings.
2. Pharmaceutical Intermediates: Production and sale of advanced intermediates and chiral intermediates including norephedrine, norpseudoephedrine, methylephedrine, oxazolidinone derivatives for pharmaceutical customers
3. Contract Development and Manufacturing (CDMO): Full-service CDMO offerings including process development, scale-up, and manufacturing for third-party pharmaceutical companies. Services include upstream/downstream development, analytical method development, and commercial production
4. Bio-fertilizers and Bio-pesticides: Crop protection and improvement products including bio-fertilizers (nitrogen-fixing, phosphate solubilizing, potassium mobilizing bacteria) and bio-pesticides (Trichoderma-based) for agricultural sector

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Embio manufactures Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals using proprietary bacterial, fungal, and Category 1 GMO biotransformation platforms, with licenses to produce Schedule-1 and Schedule-2 controlled substances and chiral molecules. The company supplies originator and multinational pharmaceutical, nutraceutical, food, cosmetic, and crop protection customers in 70+ countries from US-FDA, PMDA, KFDA, COFEPRIS, WHO-GMP, EMA, and ANVISA approved facilities. Embio also offers full-service Contract Development and Manufacturing (CDMO) covering process development, scale-up, and analytical method development, plus a crop protection product line of bio-fertilizers and bio-pesticides.

Product overview

Embio operates as a manufacturer of Active Pharmaceutical Ingredients (APIs), Intermediates, and Crop Protection products, supplemented by Contract Development and Manufacturing (CDMO) services. The company offers a portfolio of regulated market-focused APIs including pseudoephedrine, ephedrine, CBD, and specialty intermediates such as chiral molecules and controlled substances. The CDMO division provides end-to-end contract manufacturing capabilities including fermentation-based biotransformation (up to 40KL scale), downstream processing, and analytical development. Crop protection includes bio-fertilizers and bio-pesticides. Manufacturing is conducted at US-FDA, PMDA, KFDA, COFEPRIS, and WHO-GMP approved facilities in Mahad and Dahej, Gujarat.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Regulated-market focused Active Pharmaceutical Ingredients including pseudoephedrine, ephedrine, CBD, lisdexamfetamine, selegiline, and levodopa, backed by USDMF, KDMF, CEP, and DMF filings. Targeted at originator and multinational pharmaceutical companies in US, Europe, Japan, Brazil, Canada, and other regulated markets.
• Pharmaceutical Intermediates Pharmaceutical intermediates including chiral molecules, norephedrine, pseudoephedrine, ephedrine derivatives, oxazolidinones, and specialty chemical intermediates for regulated markets. Used by pharmaceutical customers as advanced starting materials for API synthesis.
• CDMO (Contract Development and Manufacturing) Full-service CDMO offering upstream/downstream process development, whole cell biotransformation, scale-up from 10L to 40KL fermentation, downstream processing, and analytical method development for GMOs under the IBSC-DSIR framework. Targeted at pharmaceutical and biotech companies outsourcing complex API and intermediate manufacturing.
• Crop Protection / Improvement Products Bio-fertilizers (nitrogen-fixing, phosphate solubilizing, potassium mobilizing bacteria), sulfur-based plant nutrients (72 MT/Annum capacity), and Trichoderma-based bio-pesticides for agricultural applications across crops such as grapes, pulses, vegetables, ginger, pomegranate, and chickpea. Targeted at farmers and agricultural producers seeking organic alternatives to chemical pesticides.

Quantifiable outcome

• Serves customers in 70+ countries across regulated markets
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• IIT Bombay (IITB)coreStrategic or Co-development PartnerResearch collaboration through think tank access arrangement. Embio leverages IITB expertise for advanced R&D activities and process development support.
• UICT (University Institute of Chemical Technology)coreStrategic or Co-development PartnerAcademic partnership for research collaboration and technical expertise access in chemical technology and process development.
• BATU (Dr. Babasaheb Ambedkar Technological University)minorStrategic or Co-development PartnerAcademic collaboration for R&D support and technical expertise in biotechnology and chemical engineering.
• Udaan India FoundationminorOthersCSR partnership supporting education for children from low income communities in Mumbai. Embio has supported Udaan for over a decade in its mission to ensure holistic education aligned with Government of India's Right to Education objectives.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Codexis: US-based enzyme engineering and biocatalysis company supplying pharma — overlaps Embio's biotransformation/synthetic biology platform but focuses on enzymes and services rather than full-scale API manufacturing.

Broad incumbents

• Novozymes (Novonesis): Global fermentation and enzyme platform leader — adjacent comparable for Embio's fermentation/biotransformation capabilities, though focused on industrial enzymes rather than pharma APIs.
• Biocon: Larger Indian biopharmaceutical company with fermentation-based API and CDMO businesses — broad incumbent with overlapping fermentation/biocatalysis capabilities though larger scale and broader biologics focus.

Direct peers

• Jubilant Pharmova: India-based pharma company with CDMO, API, and intermediates businesses serving regulated markets — directly comparable in business mix including controlled substances and complex chemistries.
• Hikal Limited: Indian manufacturer of APIs, intermediates, and specialty chemicals serving global pharma and crop science — comparable in vertical mix (pharma + agro) and B2B regulated-market model.
• Piramal Pharma Solutions: India-based CDMO offering API development, manufacturing, and biotransformation services to global pharma — overlaps Embio's CDMO arm and controlled-substance/chiral synthesis capabilities.
• Divis Laboratories: Indian API and intermediates manufacturer focused on chiral molecules and complex APIs for global generics and innovator pharma — directly comparable in product mix and regulated-market exposure.
• Dishman Carbogen Amcis: India-headquartered CRDMO offering API process development and manufacturing including chiral APIs — directly comparable to Embio's CDMO and intermediates business.
• Laurus Labs: Indian-headquartered API manufacturer with strong biotransformation, fermentation and CDMO capabilities supplying regulated markets — closest direct comparable to Embio in scale, business model, and customer base.

Regional players

• UPL Limited: Indian crop-protection and bio-fertilizer manufacturer — comparable to Embio's bio-fertilizer/bio-pesticide arm though much larger and focused exclusively on agro inputs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Embio-ltd-485006118193221
• LinkedInlinkedin.com/company/embio-limited

Compliance11 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Embio